Lundbeckfonden Ventures nyheder

DECO Study to Explore Dosing Regimen with Higher ICON-1 Dose South San Francisco, CA – May 16, 2018 – Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor (TF) biology into new therapeutics for retinal disease and cancer, announced enrollment of the first patient in its second Phase 2 study...
Lund, Sweden, 08.45 CET, 17 May 2018 – BONESUPPORT HOLDING AB (publ) announces today that the current distribution agreement has been terminated and will be replaced by a network of independent distributors and its own commercial organization. This will allow BONESUPPORT to increase its market penetration while creating a stronger platform for current products and...
Lund, Sweden, 08.00 CET, 4 May 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces the publication of its Q1 Interim Report – January – March 2018. BEST QUARTER EVER IN EUROPE FINANCIAL...
Data from Multiple Preclinical Studies Presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases SAN DIEGO – April 30, 2018 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that preclinical data demonstrating that APX001 has potent activity against deadly multidrug-resistant Candida species were presented last week at the 28th European Congress...
Lund, Sweden, 7.30 p.m. CET, 30 April 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform, has today published its 2017 Annual Report. The report summarises the business, as well as highlights for 2017, and...
Lund, Sweden, 08.00 CET, 27 April 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform, will publish its Q1 2018 Interim Report on Friday 4 May 2018 at 8am CET. The Company will also host...
Lund, Sweden, 13:00 CET 20 April 2018 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in BONESUPPORT HOLDING AB, Reg. No. 556802-2171, are hereby invited to attend the annual shareholders’ meeting (Sw. årsstämma) to be held...
Veloxis Pharmaceuticals A/S announced today that the U.S. Food & Drug Administration (FDA) has accepted for standard review the Company’s supplemental New Drug Application (sNDA) which seeks a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.  This indication is commonly...
Cambridge, UK and Indianapolis, US – 11 April 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, has made substantial progress in expanding its US commercial operations for the...
1 2 3 42

Lundbeckfonden Ventures

Nyheder

Iconic Therapeutics Initiates Second Phase 2 Study of ICON-1 in Patients with Neovascular (wet) AMD
17. maj 2018
BONESUPPORT creates its own US Commercial Platform
17. maj 2018
BONESUPPORT HOLDING AB (Publ) – Q1 Interim Report
4. maj 2018